Trial Profile
GEMCITABINE COMBINED WITH THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Temsirolimus (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Nov 2018 Results published in the Targeted Oncology
- 29 Jul 2011 New trial record